Esau815 Posted - 4 days ago

$IDXG The last PR telegraphed what's going on. 1. The two PE's gave up their preference owning 66% of the company in exchange for 81% ownership with no preference. That would point to them thinking there's more upside ahead. But of course nothing certain. 2. The goal is to get listed and do a raise to close on a deal to have a bigger company. That's in the PR. 3. PancraGen reimbursement issue has NOT gone away but for the present time looks dormant. An adverse ruling would be bad news. Every week that goes by without it is a big positive for IDXG. 4. The debt is being paid off at $500K a month and will be gone by October if reimbursement issue doesn't reappear. Once that's gone? Huge cloud goes away.

Waters59 Posted - 6 days ago

$IDXG if the 6-month channel up holds, we should hopefully be seeing above $5 in the next 6 months. Keep beating earnings and may be above that earlier. It'll need to go 3x this expected to break even after the rs crushed us, or at least it did me. ha. oh well, long term even longer.

Cujo Posted - 1 week ago

$IDXG Giddy up!

Cujo Posted - 1 month ago

$IDXG looks like a cup and handle. Target 5$

PenkeTrading Posted - 1 month ago

I found you a MACD Bearish Reversal Divergence on the daily chart of Interpace Biosciences Inc. $IDXG #BearishReversalDivergence #OTCQX

Esau815 Posted - 1 month ago

$IDXG Win-Win situation for all involved at this point due to Ampersand/1315 giving up their preference. Preference holders used to have $43MM preference prior to announcement and little else. Now they have 22MM shares at $3 plus at about $66MM Common had value of $8.5MM prior to announcement--and only if debt and preferred got paid first. Now their value is about $13MM. (Still about $5-$6MM in debt) Ampersand/1315 get much of the upside with about 26MM shares and a dilution coming to make a deal. Let's say they issue 10MM shares at $3 to make a $30MM deal and then able to list the company. All matters who they buy. Can a combined company grow to $100MM in sales? (PancraGen reimbursement issue has to go away). At $100MM and 2.5 multiplier you're at $250MM and $8. EVERYTHING would have to go right for this to occur. But things took a surprising turn on PancraGen delay--so who knows.

armanio Posted - 1 month ago

$IDXG if I have done the math right including total preferred shares conversion and the total liabilities, an acquisition at $120M translates to ~3.5$/share

apppro Posted - 1 month ago

$idxg Total crapolla

saggs22 Posted - 1 month ago

$IDXG Been here from the beginning just waiting it out…finally like the direction and outlook. Let’s keep it going

Esau815 Posted - 1 month ago

$IDXG It is apparent that someone is desperately trying to get in before the listing/unannounced merger. There are only 4.3MM outstanding common shares and over 1MM is held by large shareholder.

armanio Posted - 1 month ago

$IDXG It seems to be a perfect opportunity for an acquisition.

Esau815 Posted - 1 month ago

$IDXG Clarification from last post. Hard to ascertain exactly how much debt was paid until financials are filed with SEC. Progress being made--but not possible to determine what outstanding debt is from press release.

Esau815 Posted - 1 month ago

$IDXG Blowout quarter. Most of the debt repaid. No mention of Novitas reimbursement issue. Going to get listed, raise capital and do a deal.

apppro Posted - 1 month ago

$IDXG Q3 Revenue of $12.3 million; a $3.2M and 35% increase year-over-year ●Q3 Test volume up 26% year over year to record levels ●Q3 Cash collections of $11.3M; a $1.4M and 15% increase year-over-year ●Q3 Volume, Revenue, and Profitability at all-time record levels

Cujo Posted - 10/29/24

$IDXG bull flag, another nice move coming

Esau815 Posted - 2 months ago

$IDXG Let's be realistic. The two PE's giving up their preference in favor of dilution is an immensely positive sign. Their ownership increased from 66 to 84%. Let's say that the Pancragen reimbursement issue goes away. A big if--but maybe those guys know something we don't. Let's also say that IDXG had a killer quarter and that they're on track for $55MM in 2024 revenues--this is wildly optimistic but let's go for it. Let's also say that IDXG is NOT going to do a dilution to buy another asset once listed. I really think that's what they're intending by the way. And let's put a 2 times revenues--also generous. That's $110MM. That's $4 per share for us. The PE get $95MM which is more than double their initial $45MM investment. That's the rosiest short term scenario I can see. Long term a whole different story.

ramtek57 Posted - 2 months ago

$IDXG Way undervalued!

davoid49 Posted - 2 months ago

$IDXG NHOD $3.22

davoid49 Posted - 2 months ago

$IDXG New HOD $3.00

Esau815 Posted - 2 months ago

$IDXG Impossible to project fair value of $IDXG even with the preferred conversion. PancraGen reimbursement is still the elephant in the room. If Novitas steps back it's worth more than $2.50. If Novitas slams the door it's worth less than $2.50. How much higher or how much lower is beyond me.

Esau815 Posted - 2 months ago

$IDXG Great news but remember that preferreds will now own 84% of the company instead of 66%

pilobious Posted - 2 months ago

$IDXG so how many shares of the older Series B preferred shares remain outstanding? 47,000 were converted. What is left?

Zapp Posted - 2 months ago

$IDXG easy double from here

Gojilla24 Posted - 2 months ago

$IDXG shackles have been removed.

crane_train21 Posted - 2 months ago

$IDXG so they converted their Preferred to Common. Let the games begin.

HiEOD Posted - 2 months ago

$IDXG https://finance.yahoo.com/news/interpace-biosciences-announces-capital-restructuring-200500651.html

HiEOD Posted - 2 months ago

$IDXG

apppro Posted - 2 months ago

$IDXG may just get it today

apppro Posted - 2 months ago

@Gojilla24 $IDXG may just get it today

apppro Posted - 09/30/24

$IDXG @Gojilla24 would have been really nice to have stayed above $2.00 today